Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - TearLab Corp | ex99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
March 4, 2011
TEARLAB CORPORATION
(Exact name of registrant as specified in its charter)
|
Delaware
|
000-51030
|
59-343-4771
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
7360 Carroll Rd, Ste 200
San Diego, CA 92121
(Address of principal executive offices, including zip code)
(858) 455-6006
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
On March 4, 2011, TearLab Corporation issued a press release announcing the receipt of a communication from the U.S. Food and Drug Administration indicating that the data submitted by TearLab Corporation was not sufficient to gain approval of its CLIA Waiver categorization application for the TearLabTM Osmolarity System. The text of the press release is included as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number
|
Description
|
|
|
99.1
|
Text of Press Release dated March 4, 2011.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
TEARLAB CORPORATION
|
|||
|
By:
|
/s/ William G. Dumencu
|
||
|
William G. Dumencu
Chief Financial Officer
|
|||
Date: March 7, 2011
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
|
Text of Press Release dated March 4, 2011.
|